Jaguar Health regains Nasdaq compliance after bid price rule violation

Jaguar Health received notice on May 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), allowing its securities to remain listed and traded on Nasdaq. The compliance reinstatement follows a 816% net revenue increase in Q1 2026 versus Q1 2025, driven by a US out-license agreement for Mytesi and Canalevia-CA1.